Please login to the form below
VTE
This page shows the latest VTE news and features for those working in and with pharma, biotech and healthcare.
AbbVie’s upadacitinib aces phase III trial
Crucially for AbbvVie, there were no cases of venous thromboembolism (VTE) in the 1, 629-patent study, something that was observed in two earlier phase III studies of the drug ... Analysts said the lack of VTEs in the latest study reduced the risk in the
Latest news
-
Bad news for Portola as CHMP considers Factor Xa drugs
The CHMP communicated a negative trend vote for betrixaban for the prevention of venous thromboembolism (VTE) in adult patients hospitalised for an acute medical illness with risk factors for VTE,” said
-
Xarelto no better than aspirin in secondary stroke study
with venous thromboembolism (VTE), but a secondary stroke prevention indication would have represented a greater opportunity.
-
Xarelto beats aspirin for recurrent blood clots
risk. The results of the EINSTEIN CHOICE trial looked at the value of extended treatment of patients with venous thromboembolism (VTE). ... It's already known that after an initial few months of anticoagulant treatment for VTE, giving aspirin as a
-
BMS claims 80% market share for Opdivo in US
and Daiichi Sankyo's Savaysa (edoxaban) in both atrial fibrillation (AF) and venous thromboembolism (VTE), according to the company.
-
NICE recommends Daiichi Sankyo's Lixiana for DVT and PE
There are over 83, 000 new cases of VTE in England each year and a further 42, 000 patients require long-term anticoagulation treatment. ... A 2007 study across six European countries including the UK estimated 762, 000 VTE episodes and a further 370,
More from news
Approximately 3 fully matching, plus 45 partially matching documents found.
Latest Intelligence
-
Modern anticoagulants threaten status quo
It is indicated for the prevention of VTE after orthopaedic surgery and is administered subcutaneously once daily. ... The drug is also in phase III development for the acute treatment of VTE.
-
Case study: Using avatar technology to reduce VTE
The programme was endorsed by The Royal Pharmaceutical Society and promoted among VTE Exemplar Centres. ... Evidence from the field suggests pharmacists have been encouraged to pick up the gauntlet of VTE prevention.
-
Go with the flow
risk. VTE risk assessment has been included as a DH priority in the NHS Operating Framework 2010/11.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
WHITE PAPER: What's missing in women's health?
4. NICE guidelines recommend transdermal patches as the safest form of administration for women with a high risk of complications such as VTE.
-
NOAC Education: Empowering Stroke Prevention
Prophylactic anticoagulation is also being explored in conditions such as embolic strokes of undetermined source (ESUS) or when there is a risk of a patient developing venous thromboembolism (VTE).
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC
- Medscape Education Receives Joint Accreditation with Commendation to Deliver Continuing Education for Healthcare Providers
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
- NHS England to roll out continuous glucose monitors to all those with type 1 diabetes
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
- WHO launches funding appeal for greater Horn of Africa prompted by food crisis
PMHub
Market Access Transformation
Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...
Latest intelligence
- Animation: Living With
- The journey from the patient's perspective...
- Achieving communication excellence by targeting the right channel at the right time
- By Danny Buckland...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
